Drugs / 225Ac-J591
Trials 5 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT04576871 | Oct 2020 → Aug 2023 | prostate cancer | Weill Medical College of Cornell University | Completed | No outcome recorded |
| Phase 12 trials | ||||||
| Phase 1 | NCT04886986 | Jun 2021 → Dec 2027 expected | prostate cancer | Weill Medical College of Cornell University | Recruiting | No outcome recorded |
| Phase 1 | NCT03276572 | Oct 2017 → Jan 2021 | prostate cancer | Weill Medical College of Cornell University | Completed | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT04946370 | Aug 2021 → Oct 2027 expected | prostate cancer | Weill Medical College of Cornell University | Recruiting | No outcome recorded |
| Phase 1/2 | NCT04506567 | Aug 2020 → Jun 2025 overdue | prostate cancer | Weill Medical College of Cornell University | Active not recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 225Ac-J591 | “225Ac-J591” NCT04886986 ↗ |
| Modality | Monoclonal antibody | “225Ac-J591, anti-PSMA monoclonal antibody J591 radiolabeled with the alpha emitter actinium-225” PMID 37922438 ↗ Nov 2023 |
| Route | Intravenous | “Intravenous administration.” NCT04886986 ↗ |